Antigen News and Research

RSS

New portable device can quickly diagnose infectious disease

Infectious diseases can spread very rapidly, so quickly identifying them can be crucial to stopping an epidemic. However, current testing for such diseases can take hours and days. But not for much longer.

1 Mar 2012

iBio receives U.S. patent for fusion-protein vaccine technology

iBio, Inc. today announced issuance of a US patent covering the use of iBio's proprietary fusion-protein technology in combination with influenza virus antigens for vaccine product applications.

29 Feb 2012

USPTO issues two patents on 'Novel Shigella protein antigens and methods' to IVI

The International Vaccine Institute (IVI), an international organization based in Seoul devoted to research on the development and introduction of vaccines for the developing world, reached a milestone in its aim to prevent and control dysentery (also commonly called shigellosis or bloody diarrhea), a deadly disease that affects several million people worldwide.

27 Feb 2012

Dendreon 2011 product revenue increases to $213.5M

Dendreon Corporation today reported results for the year and quarter ended December 31, 2011. Product revenue for the year ended December 31, 2011 was $213.5 million compared to $48 million for the year ended December 31, 2010. Product revenue for the fourth quarter of 2011 was $77 million compared to $25 million for the quarter ended December 31, 2010.

27 Feb 2012

New technique effective in jumpstarting defective immune systems against many diseases

In a study published in Nature Medicine, Loyola researchers report on a promising new technique that potentially could turn immune system killer T cells into more effective weapons against infections and possibly cancer.

26 Feb 2012

Scientists decode two new blood types

You probably know your blood type: A, B, AB or O. You may even know if you're Rhesus positive or negative. But how about the Langereis blood type? Or the Junior blood type? Positive or negative? Most people have never even heard of these.

24 Feb 2012

University of Pennsylvania, IMUC enter license agreement for dendritic-cell production method

ImmunoCellular Therapeutics today announced that it has entered into an agreement with the University of Pennsylvania under which University of Pennsylvania has granted the Company an exclusive, worldwide license for a patent pending technology for the production of high-activity dendritic cells.

21 Feb 2012

Targeting patient's own dendritic cells may help restore the immune system

Aggressive ovarian tumors begin as malignant cells kept in check by the immune system until, suddenly and unpredictably, they explode into metastatic cancer. New findings from scientists at The Wistar Institute demonstrate that ovarian tumors don't necessarily break "free" of the immune system, rather dendritic cells of the immune system seem to actively support the tumor's escape.

20 Feb 2012

Biochemists determine first crystal structure of an immunoproteasome

Like a shredder, the immunoproteasome cuts down proteins into peptides that are subsequently presented on the cellular surface. The immune system can distinguish between self and nonself peptides and selectively kills cells that due to a viral infection present non-self peptides at their surface. In autoimmune diseases this mechanism is deregulated and the immune system also eliminates uninfected cells by mistake.

16 Feb 2012

Combination of therapeutic cancer vaccines and chemotherapy shows promise

Therapeutic cancer vaccines, which stimulate the body's immune system to target and destroy cancer cells, are being used in combination with conventional chemotherapy with growing success, as described in several illuminating articles in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc.

16 Feb 2012

Gen-Probe receives FDA approval for PROGENSA PCA3 assay

DiagnoCure, Inc., a Quebec life sciences company that develops and commercializes high‐value cancer diagnostic tests, announced today that the US Food and Drug Administration (FDA) has approved Gen-Probe's PROGENSA PCA3 (Prostate Cancer Antigen 3) assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.

15 Feb 2012

DC-SIGN molecule appears to play a role in fighting allergy

Scientists at The University of Nottingham have discovered a new molecule that could offer the hope of new treatments for people allergic to the house dust mite.

15 Feb 2012

Epigenetic mechanisms maintain tolerance in T cells specific for self antigens

At the most basic level, the immune system must distinguish self from non-self, that is, it must discriminate between the molecular signatures of invading pathogens (non-self antigens) and cellular constituents that usually pose no risk to health (self-antigens).

14 Feb 2012

Study investigates how cytokine IFN-λ release is regulated

In new research appearing in this month's issue of the journal Nature Immunology, Roy Curtiss, director of the Center for Infectious Diseases and Vaccinology at the Biodesign Institute at Arizona State University, along with international collaborators, investigates the coordination of a particular type of immune response, involving the release of of IFN-λ- a cell-signaling protein molecule known as a cytokine.

10 Feb 2012

Forsyth Institute to receive TB biomarkers grant from Gates Foundation

The Forsyth Institute announced today that it will receive a tuberculosis (TB) biomarkers grant through the Bill & Melinda Gates Foundation's Grand Challenges in Global Health program, an initiative which seeks to overcome persistent bottlenecks in creating new tools that can radically improve health in the developing world.

10 Feb 2012

Early-life farm environment increases number of regulatory T-lymphocytes

Immunological diseases, such as eczema and asthma, are on the increase in westernised society and represent a major challenge for 21st century medicine. A new study has shown, for the first time, that growing up on a farm directly affects the regulation of the immune system and causes a reduction in the immunological responses to food proteins.

9 Feb 2012

Routine 4CMenB immunizations effective against meningococcal strains in infants

Administration of routine infant immunizations with a vaccine for serogroup B Neisseria meningitidis, a bacterium that is a cause of serious disease such as sepsis and meningitis, was effective against meningococcal strains and produced minimal interference with the response to the routine vaccinations, according to a study in the February 8 issue of JAMA.

8 Feb 2012

Positive updated results from Aeterna Zentaris' AEZS-108 Phase 1 trial on CRPC

Aeterna Zentaris Inc. today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate cancer (CRPC) with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog.

4 Feb 2012

Novel PSAV risk count testing may effectively screen men for prostate cancer

A new study by NYU Langone Medical Center and Northwestern University Feinberg School of Medicine shows novel PSA velocity (PSAV) risk count testing may provide a more effective way for physicians to screen men for clinically significant prostate cancer.

3 Feb 2012

New England Journal of Medicine publishes Diamyd Medical's antigen-based diabetes therapy study

An article with the results of Diamyd Medical's European Phase III study of the antigen-based diabetes therapy Diamyd® has been published in the scientific journal the New England Journal of Medicine. The now published results were previously presented at the American Diabetes Association's 71st Scientific Sessions in San Diego, California, USA, on June 28, 2011.

3 Feb 2012